.avif)
.avif)
.avif)
Alkermes Email Format
Biotechnology Research
・
1,001-2,500 employees
・
Dublin, Ireland
Alkermes is a biopharmaceutical company that develops and commercializes medicines for complex psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@alkermes.com
Company Overview
Industry
Biotechnology Research
Founded
1987
Headquarters
Dublin, Ireland
Revenue
$1B-$2.5B
FUNDING Stage
Public
Website
Key Executives
Richard Pops (Chairman and Chief Executive Officer), Joshua Reed (Senior Vice President, Chief Financial Officer), Blair Jackson (Executive Vice President, Chief Operating Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Alkermes?
Alkermes uses the first.last@alkermes.com format on alkermes.com, so Jane Smith would be jane.smith@alkermes.com.
What approved medicines does Alkermes currently market in the United States?
Alkermes markets several proprietary medicines in the US, including Vivitrol for alcohol and opioid dependence, Aristada and Lybalvi for schizophrenia and bipolar I disorder, and Lumryz for narcolepsy.
Where does Alkermes have its major research and manufacturing facilities?
Beyond its headquarters in Dublin, Ireland, Alkermes operates an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio, where three of its proprietary products are produced.
How can I find and verify a specific Alkermes contact for outreach?
Tools like Clay can help you verify an Alkermes contact's email address and enrich your prospect list with accurate details before you reach out to someone at the company.
What neuroscience pipeline programs is Alkermes advancing beyond its current approved products?
Alkermes is advancing alixorexton, an OXR2 receptor agonist, in clinical studies for narcolepsy and idiopathic hypersomnia, and is also exploring the orexin pathway for conditions including MS-related fatigue, Parkinson's disease, and ADHD.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating